BillionToOne, Inc., (NASDAQ:BLLN) recently completed an upsized initial public offering, or IPO, of 5.23 million shares at $60 each, raising roughly $314 million. The company, a commercial-stage molecular diagnostics company, offers specialized tests in prenatal genetics and oncology.Its patented Quantitative Counting Templates (QCT) platform uses multiplex technology to count DNA molecules at the single-molecule level.How Analysts Reacted “There is strong appetite for high-growth, profitable diagnostic com ...